Discontinued — last reported Q3 '25
Thermo Fisher Scientific Finance Lease Liabilities remained flat by 0.0% to $196.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 2.0%, from $200.00M to $196.00M. Over 4 years (FY 2020 to FY 2024), Finance Lease Liabilities shows an upward trend with a 131.8% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Higher levels increase the company's long-term leverage and fixed-cost base, while lower levels indicate a more equity-funded or asset-light approach.
The long-term portion of obligations for leases that are classified as financing arrangements, typically involving the e...
Analyzed alongside long-term debt to determine the total contractual leverage and solvency risk of the business.
finance_lease_liabilities| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $109.00M | $200.00M | $195.00M | $200.00M | $219.00M | $210.00M | $206.00M | $202.00M | $200.00M | $190.00M | $215.00M | $207.00M | $200.00M | $202.00M | $200.00M | $196.00M | $196.00M |
| QoQ Change | — | +83.5% | -2.5% | +2.6% | +9.5% | -4.1% | -1.9% | -1.9% | -1.0% | -5.0% | +13.2% | -3.7% | -3.4% | +1.0% | -1.0% | -2.0% | +0.0% |
| YoY Change | — | — | — | — | +100.9% | +5.0% | +5.6% | +1.0% | -8.7% | -9.5% | +4.4% | +2.5% | +0.0% | +6.3% | -7.0% | -5.3% | -2.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.